← Leaderboards
Nilam Sanjib Banerjee
University Of Alabama At Birmingham
$811,975
Attributed
$1,725,350
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $697.9K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,725,350 · 2
By mechanism
R01$1,370,063 · 1
R21$355,287 · 1
Top collaborators
- Anju Bansal2 shared
- Paul A. Goepfert2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Jeffrey E Kudlow$4,356,480
- John C Chatham$14,297,780
- Chandrika J Piyathilake$5,634,935
- Warner King Huh$4,442,806
- Lori Lynn McMahon$11,899,479
Others in their field
Other Emerging Leaders on “Viral”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$160,855,334
- Leonard Freedman · Leidos Biomedical Research, Inc.$68,911,178
- John Damon Chodera · Sloan-Kettering Inst Can Research$51,025,260
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- Thomas Denny · Duke University$37,546,967
Research focus
ViralTumorigenesisOncoproteinsNeoplastic CellRetinoblastoma ProteinTumorHpv-High RiskGenotypeHuman Papillomavirus 18Malignant Oropharynx NeoplasmProliferatingProteinsSpecimenTp53 GeneCell TransformationCellsChronic InfectionCell CycleHuman PapillomavirusHuman Papillomavirus 16Human Papilloma Virus-Related Malignant NeoplasmMalignant NeoplasmsPathway Interactions3-Dimensional
Grant awards (4)
Onco-immunologic factors contributing to OPSCC among people living with HIV$697,916
R01 · FY2025 · DE
Onco-immunologic factors contributing to OPSCC among people living with HIV$672,147
R01 · FY2024 · DE
Cervical cancer derived xenografts (PDX) and organoid raft cultures to evaluate pathway specific therapeutic agents.$161,494
R21 · FY2020 · CA · contact PI
Cervical cancer derived xenografts (PDX) and organoid raft cultures to evaluate pathway specific therapeutic agents.$193,793
R21 · FY2019 · CA · contact PI